Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10281378 | 0.98 | HAVCR2 (0.47) | HAVCR2HRH4SMPD3NPC1RAB9A | |
| SCHEMBL17128162 | 0.98 | HAVCR2 (0.47) | HAVCR2HRH4SMPD3NPC1RAB9A | |
| SCHEMBL2756447 | 0.95 | — | — | |
| SCHEMBL1916539 | 0.77 | HAVCR2 (0.37) | HAVCR2PARP1PARP15PARP3TYMS | |
| SCHEMBL1916066 | 0.77 | HTR2C (0.41) | HAVCR2PARP1PARP15PARP3TYMS | |
| SCHEMBL23732125 | 0.74 | HAVCR2 (0.36) | HAVCR2NOS3NOS1NOS2 | |
| SCHEMBL12082584 | 0.74 | HRH4 (0.41) | HAVCR2HRH4PARP1PARP15PARP3 | |
| SCHEMBL214394 | 0.71 | ACHE (0.39) | HRH4SMPD3KDM4ETSHRNOS3 | |
| SCHEMBL31563608 | 0.71 | HRH4 (0.38) | HRH4SMPD3TSHRACHE | |
| SCHEMBL2254884 | 0.71 | HRH4 (0.38) | HRH4SMPD3TSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364479-B2 | Ligand-exchanged zeolite imidazolate frameworks | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2022-06-21 | — | — | US | claimed |
| US-20190282997-A1 | LIGAND-EXCHANGED ZEOLITE IMIDAZOLATE FRAMEWORKS | EXXONMOBIL RES & ENG CO (US) | 2019-09-19 | — | — | US | claimed |
| EP-4412957-B1 | EMM-68 ALUMINOSILICATE ZEOLITES, SYNTHESES, AND USES | EXXONMOBIL TECHNOLOGY & ENGINEERING COMPANY (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4486698-A1 | EMM-73 MOLECULAR SIEVE COMPOSITIONS, SYNTHESES, AND USES | ExxonMobil Technology and Engineering Company (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240425379-A1 | EMM-73 MOLECULAR SIEVE COMPOSITIONS, SYNTHESES, AND USES | ExxonMobil Technology and Engineering Company | 2024-12-26 | — | — | US | disclosed |
| EP-4466224-A1 | EMM-70 ZEOLITE COMPOSITIONS, SYNTHESES, AND USES | ExxonMobil Technology and Engineering Company (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383763-A1 | EMM-68 Aluminosilicate Zeolites, Syntheses, And Uses | EXXONMOBIL TECHNOLOGY & ENGINEERING COMPANY (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118829611-A | EMM-73 molecular sieve compositions, synthesis and uses | 埃克森美孚技术与工程公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118591508-A | EMM-70 zeolite compositions, synthesis and uses | 埃克森美孚技术与工程公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-4412957-A1 | EMM-68 ALUMINOSILICATE ZEOLITES, SYNTHESES, AND USES | ExxonMobil Technology and Engineering Company (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240239780-A1 | MODIFIED FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2024-07-18 | — | — | US | disclosed |
| EP-1412353-B1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004100996-A1 | VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS AND THEIR USE IN THE PREPARATION OF RADIOPHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |
| EP-1412353-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003008413-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
| US-4788205-A | ANTAGONISTS OF PLATELET ACTIVATING FACTOR | PFIZER INC. (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0258033-A2 | Dihydropyridine anti-allergic and anti-inflammatory agents | Pfizer Limited (GB) | 1988-03-02 | — | — | EP | disclosed |
| US-3987054-A | CORROSION INHIBITORS | PLIVA PHARMACEUTICAL AND CHEMICAL WORKS (YU) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | MAPK1, MAPK3, MAP3K1 | HAVCR2 2866/4885HRH4 790/4885SMPD3 2388/4885 |
| US-20240239780-A1 | MODIFIED FERROPORTIN INHIBITORS | SLC40A1, HAMP, TFRC | HAVCR2 656/4885HRH4 2053/4885SMPD3 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.